Arch Biopartners Income Statement

Financials in millions CAD. Fiscal year is October - September.

Millions CAD. Fiscal year is Oct - Sep.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Sep '25 Sep 30, 2025	Sep '24 Sep 30, 2024	Sep '23 Sep 30, 2023	Sep '22 Sep 30, 2022	Sep '21 Sep 30, 2021
Revenue	-	0.28	2.12	1.98	0.96	3.89
Revenue Growth	-	-87.00%	6.97%	105.63%	-75.18%	5625.22%
Cost of Revenue	-0.04	0.21	3.78	2.11	1.47	4.04
Gross Profit	0.04	0.07	-1.66	-0.13	-0.5	-0.15
Selling, General & Admin	0.89	0.99	0.95	0.81	0.47	0.56
Operating Expenses	2.51	1.2	1.8	2.77	0.49	0.67
Operating Income	-2.47	-1.13	-3.46	-2.9	-1	-0.82
Interest Expense	-0.17	-0.26	-0.39	-0.36	-0.31	-0.27
Interest & Investment Income	-	-	0	0.02	-	-
Currency Exchange Gain (Loss)	-0.09	-0.05	0.02	0.01	-0.02	-0
Other Non Operating Income (Expenses)	-0.29	-0.11	-0.1	-0.1	-0.08	-0.07
Pretax Income	-3.02	-1.55	-3.92	-3.33	-1.41	-1.17
Net Income	-3.02	-1.55	-3.92	-3.33	-1.41	-1.17
Net Income to Common	-3.02	-1.55	-3.92	-3.33	-1.41	-1.17
Net Income Growth	-	-	-	-	-	-
Shares Outstanding (Basic)	68	66	63	62	62	61
Shares Outstanding (Diluted)	68	66	63	62	62	61
Shares Change	6.01%	3.51%	1.46%	0.49%	1.36%	2.34%
EPS (Basic)	-0.04	-0.02	-0.06	-0.05	-0.02	-0.02
EPS (Diluted)	-0.04	-0.02	-0.06	-0.05	-0.02	-0.02
EPS Growth	-	-	-	-	-	-

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Sep '25 Sep 30, 2025	Sep '24 Sep 30, 2024	Sep '23 Sep 30, 2023	Sep '22 Sep 30, 2022	Sep '21 Sep 30, 2021
Gross Margin	-	24.44%	-78.05%	-6.50%	-52.13%	-3.85%
Operating Margin	-	-411.11%	-162.86%	-145.99%	-103.36%	-21.08%
Profit Margin	-	-562.70%	-184.76%	-167.71%	-145.94%	-30.10%
EBIT	-2.47	-1.13	-3.46	-2.9	-1	-0.82
EBIT Margin	-	-	-162.86%	-145.99%	-103.36%	-21.08%